NEW YORK, September 30, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA),
Biogen Inc. (NASDAQ: BIIB), Omeros Corporation (NASDAQ: OMER),
Illumina Inc. (NASDAQ: ILMN), and Merrimack Pharmaceuticals Inc.
(NASDAQ: MACK). Free research report on Arena Pharma can be
accessed at https://www.equityresearchinstitute.com/ARNA.pdf On
Tuesday, September 29, 2015, the
NASDAQ Composite ended at 4,517.32, down 0.59%, the Dow Jones
Industrial Average edged 0.30% higher, to finish the day at
16,049.13, and the S&P 500 closed at 1,884.09, up 0.12%. The
losses were broad based as five out of nine sectors ended the
session in negative. Register for your complimentary reports at the
links given below.
Arena Pharmaceuticals Inc.'s stock plummeted 9.91%, to close the
day at $1.91. The stock recorded a
trading volume of 4.75 million shares, above its three months
average volume of 2.70 million shares. Over the last one month and
over the past three months, Arena Pharmaceuticals Inc.'s shares
have lost 29.52% and 58.84%, respectively. Furthermore, the stock
has declined 44.96% since the start of this year. The company's
shares are trading 40.34% below their 50-day moving average.
Additionally, Arena Pharmaceuticals Inc. has a Relative Strength
Index (RSI) of 21.47. Sign up and read the free notes on ARNA
at:
https://www.equityresearchinstitute.com/ARNA.pdf
On Tuesday, shares in Biogen Inc. recorded a trading volume of
3.82 million shares, higher than their three months average volume
of 2.73 million shares. The stock ended the day 2.19% higher at
$278.23. Shares of the company traded
at a PE ratio of 18.82. Biogen Inc.'s stock has declined 8.38% in
the last one month, 31.12% in the previous three months and 18.04%
on YTD basis. The company is trading below its 50-day and 200-day
moving averages by 11.71% and 25.49%, respectively. Furthermore,
shares of Biogen Inc. have an RSI of 35.75. The complimentary notes
on BIIB can be downloaded in PDF format at:
https://www.equityresearchinstitute.com/BIIB.pdf
Omeros Corp.'s stock edged 0.09% higher, to close Tuesday's
session at $10.91. The stock recorded
a trading volume of 1.05 million shares, below its three months
average volume of 1.47 million shares. Over the last one month and
the previous three months, Omeros Corp.'s shares have declined
29.61% and 39.36%, respectively. Additionally, the stock has
plummeted 55.97% since the start of this year. The company is
trading 28.52% and 46.02% below its 50-day and 200-day moving
averages, respectively. Furthermore, Omeros Corp.'s stock has an
RSI of 33.67. Register for free on Equity Research Institute and
access the latest research on OMER at:
https://www.equityresearchinstitute.com/OMER.pdf
Illumina Inc.'s stock finished Tuesday's session 1.38% higher at
$169.82. A total of 3.25 million
shares were traded, which was above its three months average volume
of 1.48 million shares. Over the last one month and the previous
three months, Illumina Inc.'s shares have lost 15.81% and 22.23%,
respectively. Additionally, the stock has fallen by 8.00% since the
beginning of 2015. The company's shares are trading below their
50-day and 200-day moving averages by 17.32% and 15.10%,
respectively. Illumina Inc.'s stock traded at a PE ratio of 51.93
and has an RSI of 25.76. The complete research on ILMN is available
for free at:
https://www.equityresearchinstitute.com/ILMN.pdf
On Tuesday, shares in Merrimack Pharmaceuticals Inc. ended the
session 11.43% lower at $7.78. The
stock reported a trading volume of 2.94 million shares, above its
three months average volume of 1.41 million shares. Merrimack
Pharmaceuticals Inc.'s shares have plummeted 25.86% in the last one
month, 37.07% in the previous three months and 31.11% on YTD basis.
The company is trading 23.04% below its 50-day moving average and
29.84% below its 200-day moving average. Moreover, shares of
Merrimack Pharmaceuticals Inc. have an RSI of 26.96. Free in-depth
research on MACK is available at:
https://www.equityresearchinstitute.com/MACK.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com